New hope for duchenne: experimental drug aims to restore muscle protein

NCT ID NCT06053814

Ongoing Disease control Sponsor: NS Pharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a drug called NS-050/NCNP-03 in 20 boys with Duchenne muscular dystrophy (DMD) who have a specific genetic mutation. The drug is designed to skip a faulty section of the dystrophin gene, allowing the body to produce a shorter but still functional version of the dystrophin protein, which is essential for muscle strength. The study will first assess safety and dosing, then measure changes in dystrophin levels and muscle function over several months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NS-050/NCNP-03 (a drug designed to skip exon 50 of the dystrophin gene, helping produce a shorter but functional dystrophin protein)
What this could lead to: If successful, this drug could help boys with a specific DMD mutation produce a working version of dystrophin, potentially slowing muscle decline and improving quality of life.
What could go wrong: This is an early phase 1/2 trial with only 20 participants, so safety and effectiveness are not yet proven. The drug may not produce enough dystrophin to make a meaningful difference, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Duchenne muscular dystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DUCHENNE MUSCULAR DYSTROPHY

Contacts and locations

Locations

Alberta Children's Hospital

Calgary, Alberta, Canada
Ankara Bilkent City Hospital

Ankara, Turkey (Türkiye)
Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, 60611, United States
British Columbia Children's Hospital

Vancouver, British Columbia, Canada
Children's Hospital Colorado

Aurora, Colorado, 80011, United States
Children's Hospital Los Angeles

Los Angeles, California, 90027, United States
Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
Hyogo Medical University Hospital

Nishinomiya, Hyōgo, 663-8501, Japan
Istanbul University

Istanbul, Turkey (Türkiye)
London Health Sciences Centre

London, Ontario, Canada
Miyagi Children's Hospital

Sendai, Miyagi, 989-3126, Japan
NHO Osaka Toneyama Medical Center

Toyonaka, Osaka, 560-8552, Japan
National Center of Neurology and Psychiatry

Kodaira, Tokyo, 187-8551, Japan
National Hospital Organization Nagara Medical Center

Nagara, Gifu, 502-8558, Japan
Pusan National University Yangsan Hospital

Yangsan, Gyeongsangnam-do, South Korea
Seoul National University Hospital

Seoul, South Korea
University of Kansas Medical Center

Kansas City, Kansas, 66103, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15213, United States
Yeditepe University Kosuyolu Hospital

Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.